 Lineage Cell Therapeutics, Inc. NYSE American and TASE: LCTX, a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that interim results from its Phase 12a clinical study of its lead product candidate, OpRegen, a retinal pigment epithelium RPE cell transplant therapy currently in development for the treatment of dry age-related macular degeneration dry AMD, will be presented at the International Society for Stem Cell Research ISSCR 2020 Annual Meeting, which will be held virtually June 23 to June 27, 2020. The abstract presentation, entitled, Phase IIIa Clinical Trial of Stem Cell hESC-Derived Retinal Pigmented Epithelium RPE, OpRegen Transplantation in Advanced Dry Form Age-Related Macular Degeneration AMD: Interim Results, will be presented on Saturday June 27, 2020 by Benjamin E. Reubinoff, M.D., Ph.D., Chairman and Professor at Hadassah Medical Center, Jerusalem, Israel. The presentation will provide data from patient cohorts 1 through 4 of the clinical study. 